Vaderis Raises $152 Million and Starts HEROIC
Vaderis Therapeutics closed an oversubscribed $152 million Series B and announced initiation of the global Phase 3 HEROIC study of engasertib in moderate-to-severe hereditary hemorrhagic telangiectasia (HHT). The financing is expected to support planned…
